Nyxoah to Present at Bank of America Healthcare Conference Amid U.S. Market Expansion

Event summary

  • Nyxoah will present at the Bank of America 2026 Healthcare Conference on May 13, 2026, at 5:15 PM ET.
  • The company will also hold 1x1 meetings with institutional investors during the event.
  • Nyxoah's Genio system received FDA approval in August 2025 for a subset of adult patients with moderate to severe OSA.
  • The company completed successful IPOs on Euronext Brussels in September 2020 and NASDAQ in July 2021.

The big picture

Nyxoah's participation in the Bank of America Healthcare Conference comes at a critical juncture as it seeks to solidify its position in the U.S. market following FDA approval. The company's Genio system, a leadless and battery-free neurostimulation therapy for OSA, faces competition from established players, making its strategic messaging and investor engagement pivotal. The broader industry trend of advancing sleep disorder treatments underscores the importance of Nyxoah's technological differentiation and commercialization strategy.

What we're watching

U.S. Market Penetration
How Nyxoah will leverage its FDA approval to scale its Genio system in the U.S. market.
Investor Sentiment
Whether the conference presentation will bolster investor confidence amid competitive pressures.
Therapeutic Expansion
The pace at which Nyxoah can expand its therapeutic indications beyond current FDA-approved parameters.